BLUE BELL, Pa., Aug. 8, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the quarter ended June 30, 2011.
Total revenue was $2.4 million and $5.5 million for the three and six months ended June 30, 2011, compared to $1.1 million and $2.5 million for the same periods in 2010.
Total operating expenses for the three and six months ended June 30, 2011, were $7.6 million and $15.0 million as compared to $6.1 million and $11.9 million for the same periods in 2010.
The net loss attributable to common stockholders for the three and six months ended June 30, 2011, was $2.8 million, or $0.02 per share, and $5.2 million, or $0.04 per share, as compared with a net loss attributable to common stockholders of $7.6 million, or $0.07 per share, and $9.9 million, or $0.10 per share, for the three and six months ended June 30, 2010.
RevenueThe increase in revenue for the three and six months ended June 30, 2011 as compared with the same periods in 2010 was primarily due to an increase in revenue from the company's contract with the National Institute of Allergy and Infectious Diseases ("NIAID"). This contract revenue amounted to $1.7 million and $4.5 million for the three and six months ended June 30, 2011, as compared with $945,000 and $1.8 million for the same periods in 2010. This NIAID HIV Vaccine Design and Development Teams contract, which exceeds $25 million over five years (plus two additional option years), is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX™-GP, focused on providing coverage against a broader set of global HIV clades or sub-types.
Operating Expenses Research and development expenses for the three and six months ended June 30, 2011, were $4.5 million and $8.9 million as compared to $3.1 million and $5.8 million for the same periods in 2010. The increase was primarily due to higher clinical trial costs related to multiple clinical studies, including the initiation of the Phase II study of Inovio's cervical dysplasia/cancer DNA vaccine, VGX-3100, as well as higher costs related to work performed for the NIAID HIV contract.
Net Loss Attributable to Common Stockholders The $4.8 million and $4.7 million decrease in net loss attributable to common stockholders for the three and six months ended June 30, 2011, respectively, compared with the same periods in 2010, resulted primarily from the increase in grant revenue and increase in other income from the required quarterly revaluation of registered common stock warrants, offset by the increase in research and development as well as general and administrative expenses.
Capital Resources As of June 30, 2011, cash and cash equivalents plus short-term investments in certificates of deposit were $36.4 million, compared with $21.8 million as of December 31, 2010. This change primarily resulted from the January 2011 financing, from which the Company received net proceeds of approximately $23.0 million.
Based on management's projections and analysis, the Company believes that its cash and cash equivalents are sufficient to meet its planned working capital requirements through the third quarter of 2013.
A summary of Inovio's consolidated balance sheet and statement of operations is provided at the end of this release. The Form 10-Q providing the complete 2011 second quarter financial report can be found at: http://ir.inovio.com/secfilings.
Corporate UpdateCorporate DevelopmentDuring the first quarter of 2011, Inovio announced a three-way collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic prime-boost vaccination strategy against genotype 1 hepatitis C virus (HCV) in a Phase I clinical study. Inovio will contribute its electroporation delivery technology to this collaboration. Clinical study costs will be shared equally by the collaborators.
Subsequent to the quarter, Inovio announced it had expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against prostate cancer, CMV (cytomegalovirus), malaria, hepatitis B, RSV (respiratory syncytial virus), and MRSA (methicillin-resistant staphylococcus aureus). The amendment also encompasses a new optimized IL-12 cytokine gene adjuvant.
Clinical DevelopmentInovio reported that 91% of evaluated patients (10 of 11) that had received three vaccinations of VGX-3100, its therapeutic SynCon® cervical dysplasia/cancer DNA vaccine delivered using intramuscular electroporation, displayed strong and persistent memory T-cell responses at month nine (six months after the last vaccination). Inovio subsequently reported long-term durability of T cell immune responses of up to two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100. This data further highlights the viability of using multiple booster vaccinations with a DNA vaccine delivered using electroporation, in contrast to other non-replicating vaccine vectors that may induce unwanted immune responses against the vector after multiple vaccinations.
Inovio is continuing to set up sites and enroll patients for its Phase II clinical trial for VGX-3100, which is assessing the vaccine in women with CIN 2/3 or CIN 3 cervical dysplasias, the stages of abnormal cells preceding cervical cancer. The company expects to enroll 148 patients in 25 study centers in the U.S., South Korea, South Africa, Australia, and Canada. Data is expected in the second half of 2013.
The University of Southampton, an Inovio collaborator, is enrolling patients in its Phase II clinical trial of its DNA vaccine to treat chronic myeloid leukemia and acute myeloid leukemia using Inovio's electroporation delivery system. Interim data is expected in 2012.
Another partner, ChronTech Pharma AB, is enrolling patients in its Phase IIb clinical study of its ChronVac-C® DNA vaccine for hepatitis C virus (HCV) delivered with Inovio's proprietary electroporation DNA vaccine delivery technology in combination with standard of care. Interim data is expected in 2012.
Inovio recently reported that significant T cell and antibody responses were generated in its proof-of-principle Phase I clinical study of VGX-3400X, its preventive H5N1 (avian) influenza SynCon® DNA vaccine delivered using intramuscular (IM) electroporation (EP). VGX-3400X/EP was found to be generally safe and well tolerated at all dose levels, with no vaccine-related serious adverse events. Reported adverse events and injection site reactions were mild to moderate and required no treatment. Three of 27 subjects (11%) showed HI titers (an indicator of protection in humans) greater than 1:40 against the Vietnam (A/H5N1/1203/04) strain. Two of these three subjects also demonstrated greater than 1:40 titers against the Indonesia (A/H5N1/5/2005) strain, demonstrating cross-reactive responses.
A subset of these Phase I participants have since been given a booster vaccination delivered with Inovio's new intradermal (ID) electroporation delivery technology. In previously published preclinical studies for flu and smallpox in monkeys, ID electroporation delivery of SynCon® DNA vaccines generated greater neutralizing antibody titers than IM electroporation and protected monkeys in influenza and smallpox challenge models. Data are expected in 4Q 2011.
Inovio also launched a second Phase I clinical study as part of its universal influenza vaccine program. This trial will assess INO-3510 SynCon® vaccine for H1N1 and H5N1 influenza using its skin-targeted ID delivery device. This Phase I trial is funded in part by a recent grant from the National Institutes of Health. All 90 subjects are currently being screened and randomized. Preliminary safety and immune response data are expected in the first quarter of 2012.
Inovio expects final data from two Phase I clinical studies of its PENNVAX™-B DNA vaccine against HIV in developed countries before the end of this year. Inovio previously reported best-in-class T cell immune responses in interim results announced last November.
Preclinical DevelopmentDuring the quarter, Inovio announced compelling immune responses in a study of its multi-subtype DNA vaccine for foot-and-mouth (FMD) disease administered with electroporation in sheep. Strong protective neutralizing antibodies were also previously observed in pigs vaccinated with the same Inovio FMD vaccine. Inovio's synthetic DNA vaccine cannot cause the disease, unlike today's FMD vaccines, providing a safe approach to potentially protect against FMD and reduce its serious impact on global food supply and commerce.
Inovio reported that its INO-5150 SynCon® therapeutic DNA vaccine for prostate cancer showed remarkably strong, antigen-specific and sustainable T cell responses in monkeys. The level of T cell responses was similar to those observed in a previous monkey study of Inovio's VGX-3100 cervical dysplasia/cancer vaccine, which is now in Phase II. The multi-antigen INO-5150 was designed with the intent to help the body's immune system overcome its "self-tolerance" of cancerous cells. Inovio plans to start a Phase I clinical trial mid-year 2012.
Inovio's subsidiary, VGX Animal Health, Inc., a developer of DNA-based vaccines and therapies for companion and food animals, reported strong T cell responses from VAH-5000D, its DNA vaccine encoding telomerase reverse transcriptase (TERT) for the treatment of dogs with cancer. Human TERT (hTERT) is also associated with human cancers.
Inovio received recognition in multiple scientific journals. Vaccine published a paper entitled "Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine"; PLoS One published the paper "Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccine." The papers were co-authored by researchers from Inovio and its academic collaborators. The data demonstrated in vaccinated animals unique immune system responses, significant antigen-specific T-cell responses, and protection from the virus.
About Inovio Pharmaceuticals, Inc. Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon® vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include three separate programs in Phase II clinical studies, including VGX-3100 for treating cervical dysplasia and cancer. Other Inovio clinical programs include those for avian flu (preventive) and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 31, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.CONTACTS:Investors:
Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101Media:
Jeff Richardson, Richardson & Associates, 805-491-8313Inovio Pharmaceuticals, Inc.CONDENSED CONSOLIDATED BALANCE SHEETSJune 30,
2010 (Unaudited)ASSETSCurrent assets:Cash and cash equivalents
$ 19,998,489Short-term investments — certificates of deposit
32,887Accounts receivable from affiliated entity90,421
72,149Prepaid expenses and other current assets
273,975Prepaid expenses and other current assets from affiliated entity
653,436Total current assets38,606,721
22,877,207Fixed assets, net
276,795Intangible assets, net
10,113,371Investment in affiliated entity
259,128Total assets$ 67,857,553
$ 56,067,391LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable and accrued expenses
$ 3,410,610Accounts payable and accrued expenses due to affiliated entity
1,680,947Accrued clinical trial expenses426,471
178,328Common stock warrants
420,897Deferred revenue from affiliated entity
375,000Total current liabilities9,941,278
6,436,708Deferred revenue, net of current portion
72,780Deferred revenue from affiliated entity, net of current portion2,149,194
2,336,694Deferred rent, net of current portion
67,112Deferred tax liabilities
8,966,480Stockholders' equity:Inovio Pharmaceuticals, Inc. stockholders' equity:Common stock
105,038Additional paid-in capital
(194,838,229)Accumulated other comprehensive income
2,850Total Inovio Pharmaceuticals, Inc. stockholders' equity55,007,732
597,918Total stockholders' equity
47,100,911Total liabilities and stockholders' equity$ 67,857,553
$ 56,067,391INOVIO PHARMACEUTICALS, INCCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)Three Months Ended
Six Months Ended
June 30, 2011
2010 Revenue:License fee and milestone revenue
$ 122,495License fee and milestone revenue from affiliated entity
125,806Grant and miscellaneous revenue
2,508,248Operating expenses:Research and development
5,813,824General and administrative
6,077,751Gain on sale of assets
—Total operating expenses7,556,364
11,891,575Loss from operations(5,136,601)
(9,383,327)Other income (expense):Interest income, net
48,155Other income, net
1,704,172Loss from investment in affiliated entity
(9,914,584)Net loss/ (gain) attributable to non-controlling interest
4,460Net loss attributable to Inovio Pharmaceuticals, Inc.$ (2,822,159)
$ (9,910,124)Loss per common share — basic and diluted:Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders$ (0.02)
$ (0.10)Weighted average number of common shares
outstanding — basic and diluted127,256,364
|SOURCE Inovio Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved